Scandinavian Simvastatin Survival Study (4S)

ScandinavianScandinavian
Simvastatin SurvivalSimvastatin Survival
Study (4S)Study (4S)
The Lancet, Vol 344, November 19, 1994The Lancet, Vol 344, November 19, 1994

ObjectivesObjectives
• Randomized trial of cholesterol lowering inRandomized trial of cholesterol lowering in
4,444 patients with CAD: The Scandinavian4,444 patients with CAD: The Scandinavian
Simvastatin Survival Study.Simvastatin Survival Study.
• To investigate whether long-term simvastatinTo investigate whether long-term simvastatin
therapy reduces total mortality and coronarytherapy reduces total mortality and coronary
events in post-MI and or angina patients withevents in post-MI and or angina patients with
total cholesterol between 212-309 mg/dL.total cholesterol between 212-309 mg/dL.

DesignDesign
• Double-blind, randomized, placebo-controlledDouble-blind, randomized, placebo-controlled
− 94 centers in 5 countries94 centers in 5 countries
− 4,444 men and women 35 to 70 years of age4,444 men and women 35 to 70 years of age
− Inclusion Criteria: Prior MI and/or anginaInclusion Criteria: Prior MI and/or angina
pectorispectoris
− Total Cholesterol:Total Cholesterol: 212-309 mg/dL212-309 mg/dL
− Follow-up: until 440 deaths occurred.Follow-up: until 440 deaths occurred.

EndpointsEndpoints
• Primary:Primary: Total MortalityTotal Mortality
• Secondary:Secondary: Major adverse coronary eventsMajor adverse coronary events
• Coronary deathsCoronary deaths
• Nonfatal MIsNonfatal MIs
• Tertiary:Tertiary: Effect on:Effect on:
• PTCA/CABG proceduresPTCA/CABG procedures
• Survival without atheroscleroticSurvival without atherosclerotic
event (event-free survival)event (event-free survival)
• Any coronary eventAny coronary event
• Non-MI acute CHD eventsNon-MI acute CHD events

Treatment ScheduleTreatment Schedule
Simvastatin 20 mg/day orSimvastatin 20 mg/day or
matching placebomatching placebo
Increased to 40 mg/day if TC exceededIncreased to 40 mg/day if TC exceeded
200 mg/dL200 mg/dL
Study Goal:Study Goal:
TC 116-200 mg/dLTC 116-200 mg/dL

Dosage TitrationDosage Titration
2 0 m g / d a y
6 3 %
4 0 m g / d a y
3 7 %
2 , 2 2 1
s i m v a s t a t i n 2 0 m g / d a y
2 , 2 2 3
p l a c e b o p a t i e n t s
4 , 4 4 4
r a n d o m i z e d p a t i e n t s

Baseline CharacteristicsBaseline Characteristics
M e a n a g e (y e a rs )-m e n 5 8 .1 5 8 .2
M e a n a g e (y e a rs )-w o m e n 6 0 .5 6 0 .5
A n g in a o n ly 2 1 % 2 1 %
M I o n ly 6 2 % 6 3 %
B o th a n g in a a n d M I 1 7 % 1 6 %
H y p e rte n s io n 2 6 % 2 6 %
S m o k e r 2 7 % 2 4 %
T C (m g /d L ) 2 6 0 2 6 0
L D L (m g /d L ) 1 8 0 1 8 0
PlaceboPlacebo
(n=2223)(n=2223)
SimvastatinSimvastatin
(n=2221)(n=2221)

Primary Endpoint: Overall SurvivalPrimary Endpoint: Overall Survival
80
82
84
86
88
90
92
94
96
98
100
0 1 2 3 4 5 6
Simvastatin
Placebo
Years since randomizationYears since randomization
%Surviving%Surviving
30%
risk reduction
p = 0.0003

Coronary MortalityCoronary Mortality
111
189
0
50
100
150
200
Placebo imvastatin
42% Risk Reduction42% Risk Reduction
p<0.00001p<0.00001
NumberofdeathsNumberofdeaths

Cardiovascular MortalityCardiovascular Mortality
Coronary 189 111 42%
-Definite acute MI 63 30
-Probable acute MI 5 5
-Sudden death 78 46
-Other 43 30
Cerebrovascular 12 14
Other cardiovascular 6 11
All cardiovascularAll cardiovascular 207207 136136 35%35%
Cause of deathCause of death
PlaceboPlacebo
(n=2223)(n=2223)
(n=2221)(n=2221)
RiskRisk
ReductionReduction

All Cause MortalityAll Cause Mortality
C o ro n a ry 1 8 9 1 1 1 4 2 %
N o n c o ro n a ry
v a s c u la r
1 8 2 5
N o n -c a rd io v a s c u la r 4 9 4 6
-C a n c e r 3 5 3 3
-S u ic id e 4 5
-T ra u m a 3 1
-O th e r 7 7
Cause of deathCause of death
PlaceboPlacebo
(n=2223)(n=2223)
(n=2221)(n=2221)
RiskRisk
ReductionReduction
All DeathsAll Deaths 256256 182182 30%30%

Causes of DeathCauses of Death
111
1314
3335
2518
189
Placebo Simvastatin
Other Cancer Other Cardiovascular Coronary
11.5%11.5%
8.2%8.2%

60
70
80
90
100
0 1 2 3 4 5 6
Simvastatin
Placebo
Coronary Death and Nonfatal MICoronary Death and Nonfatal MI
%ofpatientswithoutevents%ofpatientswithoutevents
34%34%
Risk ReductionRisk Reduction
p<0.00001p<0.00001

Need for PTCA/CABGNeed for PTCA/CABG
70
75
80
85
90
95
100
0 1 2 3 4 5 6
Simvastatin
Placebo
%ofpatientswithout%ofpatientswithout
PTCA/CABGPTCA/CABG
37%37%
RiskRisk
ReductionReduction
p<0.00001p<0.00001

Endpoint by GenderEndpoint by Gender
12.8
6
29.4
21.7
8.5
6.6
20.5
14.5
0
5
10
15
20
25
30
35
Male Female Male Female
Total Mortality Major Coronary Events
%Incidence
Placebo
Simvastatin

Endpoints by AgeEndpoints by Age
8.1
14.8
27.6 28.3
5.2
11
17.6
21
0
5
10
15
20
25
30
35
<60 yrs >60 yrs <60 yrs >60 yrs
Total Mortality Major Coronary Events
%Incidence
Placebo
Simvastatin

Event-Free SurvivalEvent-Free Survival
50
60
70
80
90
100
110
0 1 2 3 4 5 6
Simvastatin
Placebo
Survival without atherosclerotic eventSurvival without atherosclerotic event
%ofpatientsalivewithout%ofpatientsalivewithout
anatheroscleroticeventanatheroscleroticevent
26%26%
RiskRisk
ReductionReduction
p<0.00001p<0.00001

Cholesterol ParametersCholesterol Parameters
-38
-28
8
-50
-40
-30
-20
-10
0
10
20
LDL TC HDL
Mean%changeMean%change
Simvastatin 20 mg, week 6Simvastatin 20 mg, week 6
p<0.0001p<0.0001

Changes in Lipoprotein LevelsChanges in Lipoprotein Levels
-25
-35
8
-10
1 1
7 7
-50
-40
-30
-20
-10
0
10
20
TC LDL HDL TGs
%Change
Simvastatin
Placebo
Simvastatin vs placebo, at study endSimvastatin vs placebo, at study end

Safety ProfileSafety Profile
N o n fa ta l c a n c e r 6 1 5 7
A S T 3 x U L N 2 3 2 0
A L T 3 x U L N 3 3 4 9
C P K 1 0 x U L N 1 6
R h a b d o m y o lis is 0 1
# of patients with# of patients with
PlaceboPlacebo
(n=2223)(n=2223)
(n=2221)(n=2221)

Summary of Key End-point ResultsSummary of Key End-point Results
Simvastatin BetterSimvastatin Better
Total mortalityTotal mortality
CAD mortalityCAD mortality
Major coronaryMajor coronary
eventsevents
PTCA/CABGPTCA/CABG
Event-freeEvent-free
survivalsurvival
0.20.2 0.40.4 0.60.6 0.80.8 1.01.0 1.21.2
p=0.0003p=0.0003
p<0.00001p<0.00001
p<0.00001p<0.00001
p<0.00001p<0.00001
p<0.00001p<0.00001
Relative risk (95% CI)Relative risk (95% CI)
Reduced Increased
Placebo BetterPlacebo Better

• Overall Riskof Death 30% Only trial to date with cholesterol lowering agent to definitively
showreduction in total or coronary mortality
• Riskof CoronaryDeath 42% Cardiovascular disease is theworld’s leading cause of death
accounting for one-fourth of all deaths
• Riskof MajorCoronary
Events 34%
Includes death from coronary disease and non-fatal heart attacks
• Riskof Revascularization
Procedures 37%
Includes percutaneous coronary angioplasties (PTCA) andcoronary
artery bypass grafts (CABG).
• Event-freeSurvival 26% Finished the study without suffering any coronary events orother
atheroscleotic events such as stroke
• LDL Cholesterol
38%*
Human atherosclerotic plaques primarily contain LDL cholesterol
• HDL Cholesterol
8%*
Highconcentrations of HDL may protect against coronary heart
disease.
• Total Cholesterol
28%*
Simvastatin is the most effective cholesterol-lowering agentavailable
at recommended doses
EndpointEndpoint CommentComment
Relative RiskRelative Risk
* After 6 weeks of treatment with 20mg* After 6 weeks of treatment with 20mg

4S Summary4S Summary
• Improved survivalImproved survival
• Reduced coronary mortalityReduced coronary mortality
• Reduced major coronary eventsReduced major coronary events
• Reduced need for PTCA and CABGReduced need for PTCA and CABG
Improved event-free survivalImproved event-free survival
• Substantially reduced TC and LDLSubstantially reduced TC and LDL
Compared with Placebo, Simvastatin:Compared with Placebo, Simvastatin:

Scandinavian Simvastatin Survival Study (4S)

Recommended

Recommended

More Related Content

What's hot

What's hot (20)

Similar to Scandinavian Simvastatin Survival Study (4S)

Similar to Scandinavian Simvastatin Survival Study (4S) (20)

Scandinavian Simvastatin Survival Study (4S)